State of the Neoadjuvant Therapy for Glioblastoma Multiforme

State of the Neoadjuvant Therapy for Glioblastoma Multiforme—Where Do We Stand? Publisher

Summary: Glioblastoma’s tough fight! Review finds neoadjuvant therapies underexplored vs other cancers; chemoradiotherapy standard fails to boost survival. Study calls for new pre-surgery trials. Hope for GBM? #Glioblastoma #NeuroOncology

Nabian N^{1, 2} ; Ghalehtaki R^{1, 2} ; Zeinalizadeh M³ ; Balana C⁴ ; Jablonska PA⁵

Source: Neuro-Oncology Advances Published:2024

Abstract

Glioblastoma multiforme (GBM) is the most common malignant primary brain tumor in adults. Despite several investigations in this field, maximal safe resection followed by chemoradiotherapy and adjuvant temozolomide with or without tumor-treating fields remains the standard of care with poor survival outcomes. Many endeavors have failed to make a dramatic change in the outcomes of GBM patients.This study aimed to review the available strategies for newly diagnosed GBM in the neoadjuvant setting, which have been mainly neglected in contrast to other solid tumors. © The Author(s) 2024. Published by Oxford University Press, the Society for Neuro-Oncology and the European Association of Neuro-Oncology.

Related Docs

View other Related Docs

1. Postoperative Neoadjuvant Temozolomide Followed by Chemoradiotherapy Versus Upfront Chemoradiotherapy for Glioblastoma Multiforme (Neotem) Trial: Interim Results, Neuro-Oncology Advances (2024)

2. Is Add-On Bevacizumab Therapy to Temozolomide and Radiotherapy Associated With Clinical Utility for Newly Diagnosed Glioblastoma? a Systematic Review and Meta-Analysis, Neurosurgical Review (2024)

3. Preferred Imaging for Target Volume Delineation for Radiotherapy of Recurrent Glioblastoma: A Literature Review of the Available Evidence, Journal of Personalized Medicine (2024)

Experts (# of related papers)

View all Related Experts

Alireza Khoshnevisan (3)

Kavous Firouznia (1)

State of the Neoadjuvant Therapy for Glioblastoma Multiforme—Where Do We Stand?

Style	Citing Format
MLA	Nabian N, et al.. "State of the Neoadjuvant Therapy for Glioblastoma Multiforme—Where Do We Stand?." Neuro-Oncology Advances, vol. 6, no. 1, 2024, pp. -.
APA	Nabian N, Ghalehtaki R, Zeinalizadeh M, Balana C, Jablonska PA (2024). State of the Neoadjuvant Therapy for Glioblastoma Multiforme—Where Do We Stand?. Neuro-Oncology Advances, 6(1), -.
Chicago	Nabian N, Ghalehtaki R, Zeinalizadeh M, Balana C, Jablonska PA. "State of the Neoadjuvant Therapy for Glioblastoma Multiforme—Where Do We Stand?." Neuro-Oncology Advances 6, no. 1 (2024): -.
Harvard	Nabian N et al. (2024) 'State of the Neoadjuvant Therapy for Glioblastoma Multiforme—Where Do We Stand?', Neuro-Oncology Advances, 6(1), pp. -.
Vancouver	Nabian N, Ghalehtaki R, Zeinalizadeh M, Balana C, Jablonska PA. State of the Neoadjuvant Therapy for Glioblastoma Multiforme—Where Do We Stand?. Neuro-Oncology Advances. 2024;6(1):-.
BibTex	@article{ author = {Nabian N and Ghalehtaki R and Zeinalizadeh M and Balana C and Jablonska PA}, title = {State of the Neoadjuvant Therapy for Glioblastoma Multiforme—Where Do We Stand?}, journal = {Neuro-Oncology Advances}, volume = {6}, number = {1}, pages = {-}, year = {2024} }
RIS	TY - JOUR AU - Nabian N AU - Ghalehtaki R AU - Zeinalizadeh M AU - Balana C AU - Jablonska PA TI - State of the Neoadjuvant Therapy for Glioblastoma Multiforme—Where Do We Stand? JO - Neuro-Oncology Advances VL - 6 IS - 1 SP - EP - PY - 2024 ER -

Science Communicator Platform

Authors

Abstract